{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0"},{"groupId":"OG001","value":"7.9"}]}],"title":"Injection method may be painful: strongly agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.6"},{"groupId":"OG001","value":"33.3"}]}],"title":"Injection method may be painful: agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"9.6"}]}],"title":"Injection method may be uncomfortable: strongly agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8"},{"groupId":"OG001","value":"25.9"}]}],"title":"Injection method may be uncomfortable: agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2"},{"groupId":"OG001","value":"4.8"}]}],"title":"Injection method may result in side effects: strongly agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9"},{"groupId":"OG001","value":"45.2"}]}],"title":"Injection method may result in side effects: agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2"},{"groupId":"OG001","value":"21.1"}]}],"title":"Injection method will save me time: strongly agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8"},{"groupId":"OG001","value":"51.8"}]}],"title":"Injection method will save me time: agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9"},{"groupId":"OG001","value":"7.9"}]}],"title":"Study medication may result in side effects: strongly agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5"},{"groupId":"OG001","value":"44.3"}]}],"title":"Study medication may result in side effects: agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7"},{"groupId":"OG001","value":"26.8"}]}],"title":"Study medication would be worth taking: strongly agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.0"},{"groupId":"OG001","value":"47.8"}]}],"title":"Study medication would be worth taking: agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2"},{"groupId":"OG001","value":"62.3"}]}],"title":"Ever received medication through IV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8"},{"groupId":"OG001","value":"61.4"}]}],"title":"Ever received medication through SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2"},{"groupId":"OG001","value":"6.1"}]}],"title":"Neither received medication ever via IV or SC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"description":"Percentage of participants who responded that they strongly agree or agree at baseline with expectations of pain, discomfort and side effects from the injection method, the injection method would save time, study medication may result in side effects and would be worth taking are reported. PEQ-BL consisted of 7 items. Percentage of participants who ever received medication through IV and/or SC administration are also reported. Percentages are rounded off to the tenth decimal place. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"NUMBER","populationDescription":"The ITT population included all randomized population. Only those participants with data collected at Baseline are reported.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1 Day 1)","title":"Percentage of Participants With Response to 'Patient Expectation Questionnaire at Baseline (PEQ-BL)'","type":"SECONDARY","unitOfMeasure":"percentage of participants"}